Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…
AD-214 Found Safe in Animal Studies, Phase 1 Trial in Humans Now Planned, AdAlta Announces
Ah, November. Tis the season for declining mental health! The end of fall and beginning of winter always make me anxious. In the past, it was the start of my competitive ski racing season that caused a lot of stress. After that were college midterms. There is no particular…
Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a study suggests. The study, “Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis,” was published in the journal Science Translational Medicine. Fibrosis — abnormal…
Before I got sick, my life was pretty straightforward. I knew what I wanted to study in college, and I earned my bachelor’s and master’s degrees. And although I have struggles in the workplace due to living with idiopathic pulmonary fibrosis (IPF), I am lucky to have a career…
MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung damage and poorer survival in Chinese patients with idiopathic pulmonary fibrosis (IPF), a study has revealed. The study, “The relationship between MUC5B promoter, TERT polymorphisms and telomere…
A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is associated with the presence of pulmonary fibrosis in patients with systemic sclerosis, but it does not represent a risk factor for worsening of skin fibrosis in these patients, a…
Managing a chronic illness is not for the faint of heart. Learning to live with idiopathic pulmonary fibrosis (IPF) is the hardest thing I’ve ever done. I applaud my colleagues at Bionews Services and the friends I’ve made around the world who share their stores and advocate for others.
People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, or radiotherapy, a study from South Korea reports. The study “Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in…
It’s been seven months since my mom, Holly, had a double-lung transplant. She and the miracle organs that have been stitched within her are going strong. But their relationship hasn’t been perfect. My mom’s body and her new lungs each brought their own baggage to the relationship.
First IPF Patient Dosed in Phase 1 Trial of Potential Oral Anti-fibrotic Therapy, Indalo Announces
Indalo Therapeutics announced that dosing has begun in the first patient enrolled in its Phase 1 trial assessing the safety, tolerability, and properties of IDL-2965, the company’s lead candidate to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). IDL-2965 is an oral, selective antagonist of three types…
Your PF Community
Recommended Posts
- DNA changes in lungs may influence disease risk in IPF: Study
- Volunteering allows me to be of service to my community
- Pulmonary fibrosis pushed my husband to pivot in his career
- Protein linked to mechanical stress drives pulmonary fibrosis: Study
- I’m living proof of the profound impact of organ donation
